Stay updated with breaking news from Otsuka Astex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The funding will advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and neurologic conditions.New investors include Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises.CARMEL, Ind.--(BUSINESS WIRE)--#TYK2--Sudo Biosciences (“Sudo”), a biophar...
/PRNewswire/ -- AstronauTx Ltd. ("AstronauTx"), a biotech company developing novel treatments for Alzheimer's disease and other neurodegenerative disorders,...
/PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced a Series B extension...
Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- Transine Therapeutics ('Transine'), a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP®...